Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience.
BACKGROUND
According to the International Federation of Gynecology and Obstetrics (FIGO) guidelines, every patient diagnosed with ovarian cancer (OC) should undergo a complete staging procedure to adequately assess tumor spread. The role of lymphadenectomy in the initial management of primary early mucinous ovarian cancer (MOC) remains unclear.


OBJECTIVE
To describe the prevalence of pelvic and para-aortic node metastases in MOC.


METHODS
The records of patients with MOC treated at our Institute during January 2005 to December 2011 were assessed. A descriptive and comparative analysis was conducted. Overall survival (OS) and diseases-free period (DFP) were calculated with the Kaplan-Meier method and were compared with the log-rank test.


RESULTS
Of 31 patients with MOC, 14 (45.16%) underwent lymphadenectomy, obtaining 190 pelvic nodes, with a median of 9 pelvic lymph nodes removed per patient (interquartile range = 15). There was no evidence of metastatic disease in the dissected pelvic nodes.


CONCLUSIONS
These results suggest that complete surgical staging with lymph node dissection has no effect on recurrence, disease-free period, and overall survival of patients with early stage MOC.
Department of Gynecology, Instituto Nacional de Cancerología, Mexico. Electronic address: ivansalgado22@hotmail.com.
Ivan
I
Salgado-Ceballos
Clinical Research, Instituto Nacional de Cancerología, Mexico City, Mexico. Electronic address: jazzerg86@gmail.com.
Jazmín
J
Ríos
Department of Pathology, Instituto Nacional de Cancerología, Mexico. Electronic address: madeliapmg@hotmail.com.
Delia
D
Pérez-Montiel
Clinical Research, Instituto Nacional de Cancerología, Mexico City, Mexico. Electronic address: dra.ngallardo@yahoo.com.
Lenny
L
Gallardo
Department of Gynecology, Instituto Nacional de Cancerología, Mexico. Electronic address: sbarquet@gmail.com.
Salim
S
Barquet-Muñoz
Department of Gynecology, Instituto Nacional de Cancerología, Mexico. Electronic address: rosasalher@gmail.com.
Rosa
R
Salcedo-Hernández
Laboratory of Genomics, Instituto Nacional de Cancerología, Mexico. Electronic address: carlos.pplas@gmail.com.
Carlos
C
Pérez-Plasencia
Director of Research, Instituto Nacional de Cancerología, Mexico. Electronic address: metil@hotmail.com.
Luis Alonso
LA
Herrera
Clinical Research, Instituto Nacional de Cancerología, Mexico City, Mexico. Electronic address: dcantude@gmail.com.
David Francisco
DF
Cantú de León
D002288:Adenocarcinoma, Mucinous / Q000401:mortality* / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D001013:Aorta, Thoracic; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods / Q000706:statistics & numerical data*; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008800:Mexico; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D010388:Pelvis; D012189:Retrospective Studies
Early stage; Lymph node metastasis; Lymphadenectomy; Mucinous ovarian cancer